Post hoc analysis of reactogenicity trends between dose 1 and dose 2 of the adjuvanted recombinant zoster vaccine in two parallel randomized trials

Post hoc analysis of reactogenicity trends between dose 1 and dose 2 of the adjuvanted recombinant zoster vaccine in two parallel randomized trials

In two large clinical trials (ZOE-50 [NCT01165177] and ZOE-70 [NCT01165229]), two doses of the adjuvanted recombinant zoster vaccine (RZV) demonstrated >90% efficacy against herpes zoster in adults ≥50 years of age. Solicited adverse events (AEs) were collected for 7 days post-each dose in a stud...

Полное описание

Библиографические подробности
Главные авторы: Romulo Colindres, Valentine Wascotte, Alain Brecx, Christopher Clarke, Caroline Hervé, Joon Hyung Kim, Myron J. Levin, Lidia Oostvogels, Toufik Zahaf, Anne Schuind, Anthony L. Cunningham
Формат: Статья
Язык:English
Опубликовано: Taylor & Francis Group 2020-11-01
Серии:Human Vaccines & Immunotherapeutics
Предметы:
recombinant herpes zoster vaccine
reactogenicity
doses
healthcare professionals
adverse events
Online-ссылка:http://dx.doi.org/10.1080/21645515.2020.1741312

Internet

http://dx.doi.org/10.1080/21645515.2020.1741312

Схожие документы